Welcome to our dedicated page for Exicure news (Ticker: XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.
Exicure Inc (XCUR) is a pioneering biotechnology company developing nucleic acid therapies through its proprietary Spherical Nucleic Acid (SNA) platform. This page serves as the definitive source for verified news and press releases related to the company’s advancements in immunomodulatory treatments, gene silencing innovations, and therapeutic applications across oncology, inflammatory disorders, and neurological conditions.
Access real-time updates on Exicure’s clinical progress, regulatory milestones, and strategic partnerships. Our curated collection includes announcements on SNA technology breakthroughs, trial results, and research collaborations, providing stakeholders with a comprehensive view of the company’s scientific and operational trajectory.
Key content categories include clinical trial updates, regulatory filings, technology licensing agreements, and peer-reviewed research highlights. Each update is structured to help investors and researchers assess Exicure’s position in the competitive biotech landscape while maintaining strict adherence to factual reporting standards.
Bookmark this page for streamlined access to Exicure’s latest developments, and check back regularly for authoritative insights into one of biotechnology’s most innovative nucleic acid delivery platforms.
Exicure (XCUR) has reached a significant milestone in its Phase 2 clinical trial of GPC-100 (burixafor), having dosed 19 patients to evaluate stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplant. The open-label, multi-center trial assesses GPC-100 and propranolol combined with G-CSF.
Interim analysis data from 10 patients presented at the 2024 ASH Annual Meeting showed promising results, with 100% of patients achieving successful CD34+ stem cell mobilization, including those previously treated with daratumumab. A key advantage of GPC-100 is its same-day administration and leukapheresis capability, offering faster treatment compared to FDA-approved alternatives like plerixafor and motixafortide.
The study reported median neutrophil and platelet engraftment times of 11 and 14 days respectively, aligning with standard care expectations. Patient recruitment is scheduled to conclude by the end of April.
Exicure (XCUR) has announced plans for a new clinical trial of its lead asset GPC-100 (burixafor) in Acute Myeloid Leukemia (AML). The CXCR4 inhibitor has shown promise when combined with modern AML treatments. A previous Phase 1 study with 15 relapsed/refractory AML patients evaluated GPC-100's safety and preliminary efficacy in combination with fludarabine and cytarabine.
Recent preclinical data presented at the 2024 ASH Annual Meeting demonstrated improved chemotherapy response through dual inhibition of CXCR4 with GPC-100 and beta-2 adrenergic receptor blockade. The company has secured patents for this approach in multiple countries.
GPC-100 is currently in a Phase 2 trial for multiple myeloma patients undergoing autologous stem cell transplant, with results expected in Q4 2025. Exicure is also exploring potential expansions into sickle cell disease, pediatric oncology, and cell and gene therapy applications.
Exicure (XCUR) reported its full year 2024 financial results, showing a mixed financial picture. The company's cash position improved to $12.5 million as of December 31, 2024, compared to $0.8 million in 2023. However, management expressed substantial doubt about continuing operations, stating additional financing is needed.
The company reported zero R&D expenses in 2024, down from $1.4 million in 2023, reflecting the complete suspension of all research activities. G&A expenses decreased to $5.4 million from $11.7 million in 2023. The net loss improved to $9.7 million in 2024 from $16.9 million in 2023.
Following its September 2022 strategic shift, which included workforce reduction and suspension of all R&D activities, Exicure continues exploring strategic alternatives to maximize stockholder value, including potential partnerships with companies interested in joining a publicly-traded organization.
Exicure (Nasdaq: XCUR) has secured Patent No. 2018388302 from the Australian Patent Office for its 'GPCR Heteromer Inhibitors and Uses Thereof.' The patent covers a novel combination approach to cancer treatment targeting CXCR4 and GPCRx.
The patent supports Exicure's ongoing Phase 2 clinical trial (NCT05561751) evaluating the combination of GPC-100 and propranolol in multiple myeloma patients. The method aims to enhance hematopoietic stem cell mobilization through co-targeting CXCR4 and ADRB2, potentially improving the efficacy of CXCR4 inhibitors like GPC-100.
The patent has already been granted in the United States, Japan, and Taiwan, with applications pending in other jurisdictions.
Exicure (XCUR) has announced a significant strategic move by acquiring GPCR Therapeutics USA Inc., a California-based and former wholly-owned subsidiary of Korean GPCR Therapeutics Inc. The acquisition was executed through a Share Purchase Agreement on January 19, 2025.
Concurrent with the acquisition, Exicure and GPCR entered into a License and Collaboration Agreement focused on developing and commercializing GPCR's technologies. Under this agreement, Exicure commits to milestone payments tied to clinical trials, marketing authorizations, and net sales achievements. The agreement includes a minimum 10% royalty payment on net sales, with specific milestones such as a $30 million payment when first annual net sales exceed $400 million.
Exicure (NASDAQ: XCUR) has announced a significant strategic move through a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean The agreement, executed on January 19, 2025, involves Exicure's acquisition of all issued and outstanding equity securities of GPCR Therapeutics USA Inc., a California-based previously wholly owned by GPCR.
Concurrent with this acquisition, both companies established a License and Collaboration Agreement (L&C Agreement) focused on developing and commercializing GPCR's technological intellectual properties and patents. Under the terms of the L&C Agreement, Exicure commits to:
- Making milestone payments tied to clinical trials progress
- Marketing authorization achievements
- Net sales performance
- Paying a recurring royalty of at least 10% on net sales
Exicure (XCUR) has signed an MOU with GPCR Therapeutics to acquire its US subsidiary, GPCR USA, and collaborate on drug development pipelines. The deal includes technology transfer of GPCR's CXCR4 inhibitor, currently in Phase 2 clinical trials, with an estimated market size of $1-2 billion annually. The acquisition targets multiple myeloma and acute myeloid leukemia (AML) treatments.
The company has secured total funding of $12 million ($8.7M on Dec 24, $2M on Dec 9, and $1.3M in November) with an additional expected $4M, totaling $14M. These funds will support the GPCR USA acquisition, clinical trials, and operations. GPCR Therapeutics recently presented three exhibits at the ASH conference, including Phase 2 trial interim results and preclinical data on T cell responses.
Exicure (XCUR) announced stockholder approval of an $8.7 million equity financing from HiTron Systems, following an initial $1.3 million investment in November. The total $10 million investment at $3 per share will make HiTron Exicure's largest shareholder with over 50% ownership. The company also received $2 million from SangSangIn Investment & Securities through the sale of 433,332 shares at $4.61 per share.
The Board expanded to nine directors with four new appointments. The company is in discussions with a US therapeutics company, with updates expected in January. Following a Nasdaq notification about non-compliance with the $2.5 million stockholders' equity requirement, Exicure presented its compliance plan on December 17, 2024, and believes recent investments will help meet listing requirements.
Exicure (XCUR) has announced significant developments following its December 17, 2024 Special Meeting of Stockholders. Shareholders approved a $8.7 million equity financing from HiTron Systems Inc., a South Korean public company. This follows an initial $1.3 million investment, bringing HiTron's total investment to $10 million at $3 per share.
The company has undergone major changes, including the appointment of Andy Yoo as CEO and four new directors, expanding the board to nine members. HiTron will become Exicure's majority shareholder with over 50% ownership upon closing of the second investment.
Additionally, Exicure secured $2 million from institutional investors and plans to raise another $2.4 million, targeting total fundraising of approximately $15 million. The company is in discussions with a US therapeutics company and expects to provide updates in January. These investments are important for maintaining Nasdaq listing compliance, addressing the minimum $2.5 million stockholders' equity requirement.
Exicure (XCUR) has entered into two purchase agreements with HiTron Systems for equity financing totaling $10 million. The first agreement, for $1.3 million (433,333 shares at $3.00/share), is expected to close within 10 days. The second agreement for $8.7 million (2,900,000 shares at $3.00/share) requires stockholder approval. For Q3 2024, the company reported cash position of $0.3 million, down from $0.8 million in December 2023, and a net loss of $1.1 million compared to $5.3 million in Q3 2023. The company faces continued listing challenges with Nasdaq and requires immediate additional funding to continue operations.
